SEC Form 4 · accession 0001094891-17-000227
PAVmed Inc. · PAVM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Lishan Aklog
Officer — Chairman and CEO · Director · 10% Owner
HCFP/Capital Partners III LLC
10% Owner
Pavilion Venture Partners LLC
10% Owner
Period of report
Aug 29, 2017
Accepted (ET)
Sep 5, 2017 · 7:53 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001624326
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 29, 2017 | P$0 | 1,412 | — | A | 60,289 | D | |
| Common StockF2 | Aug 30, 2017 | P$0 | 300 | — | A | 60,589 | D | |
| Common StockF3 | Aug 31, 2017 | P$0 | 1,600 | — | A | 62,189 | D | |
| Common StockF4 | Sep 1, 2017 | P$0 | 300 | — | A | 62,489 | D | |
| Common Stock | holding | — | — | — | 285 | I | By daughter | |
| Common Stock | holding | — | — | — | 300 | I | By son | |
| Common StockF8 | holding | — | — | — | 5,713,879 | I | By HCFP/Capital Partners III LLC | |
| Common StockF9 | holding | — | — | — | 2,520,532 | I | By Pavilion Venture Partners LLC | |
| Common StockF10 | holding | — | — | — | 87,020 | I | By HCFP Inc. | |
| Common StockF11 | holding | — | — | — | 125,000 | I | By HCFP/Capital Partners IIIB LLC | |
| Common StockF12 | holding | — | — | — | 20,000 | I | By HCFP/AG LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantsF5 | $5.00 | Aug 29, 2017 | P | 1,200 | A | Oct 28, 2016 | Jan 29, 2022 | Common Stock | 1,200 | 46,500 | D |
| Warrants | $5.00 | Aug 30, 2017 | P | 200 | A | Oct 28, 2016 | Jan 29, 2022 | Common Stock | 200 | 46,700 | D |
| WarrantsF6 | $5.00 | Aug 31, 2017 | P | 1,700 | A | Oct 28, 2016 | Jan 29, 2022 | Common Stock | 1,700 | 48,400 | D |
| WarrantsF7 | $5.00 | Sep 1, 2017 | P | 200 | A | Oct 28, 2016 | Jan 29, 2022 | Common Stock | 200 | 48,600 | D |
| WarrantsF8 | $5.00 | holding | — | — | — | Oct 28, 2016 | Jan 29, 2022 | Common Stock | 5,713,879 | 5,713,879 | I |
| WarrantsF9 | $5.00 | holding | — | — | — | Oct 28, 2016 | Jan 29, 2022 | Common Stock | 2,220,532 | 2,220,532 | I |
| WarrantsF10 | $5.00 | holding | — | — | — | Oct 28, 2016 | Jan 29, 2022 | Common Stock | 387,020 | 387,020 | I |
| WarrantsF11 | $5.00 | holding | — | — | — | Oct 28, 2016 | Jan 29, 2022 | Common Stock | 125,000 | 125,000 | I |
| WarrantsF12 | $5.00 | holding | — | — | — | Oct 28, 2016 | Jan 29, 2022 | Common Stock | 20,000 | 2,000 | I |
Explanation of responses
- F1The shares were purchased at a weighted average price of approximately $4.19770538 per share. These shares were purchased in multiple transactions at prices ranging from $4.18 to $4.20, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4.
- F10Dr. Aklog is a controlling shareholder of HCFP Inc., and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.
- F11Dr. Aklog is a member and a co-manager of the entity that acts as sole manager of HCFP/Capital Partners IIIB LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his pecuniary interest therein.
- F12Dr. Aklog is a co-manager of HCFP/AG LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his pecuniary interest therein.
- F2The shares were purchased at a weighted average price of approximately $4.19666667 per share. These shares were purchased in multiple transactions at prices ranging from $4.19 to $4.20, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4.
- F3The shares were purchased at a weighted average price of approximately $4.2725 per share. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.40, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4.
- F4The shares were purchased at a weighted average price of approximately $4.45666667 per share. These shares were purchased in multiple transactions at prices ranging from $4.39 to $4.50, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4.
- F5The warrants were purchased at a weighted average price of approximately $1.4875 per warrant. These warrants were purchased in multiple transactions at prices ranging from $1.18 to $2.24, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4.
- F6The warrants were purchased at a weighted average price of approximately $1.0375 per warrant. These warrants were purchased in multiple transactions at prices ranging from $1.01 to $1.09, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4.
- F7The warrants were purchased at a weighted average price of approximately $1.19 per warrant. These warrants were purchased in multiple transactions at prices ranging from $1.18 to $1.20, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4.
- F8Dr. Aklog is a member and a co-manager of HCFP/Capital Partners III LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.
- F9Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and has sole voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.